Literature DB >> 29581598

Formulary Drug Reviews: Glecaprevir/Pibrentasvir.

Terri L Levien1, Danial E Baker1.   

Abstract

Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are available online to subscribers. Monographs can be customized to meet the needs of a facility. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service, contact Wolters Kluwer customer service at 866-397-3433.

Entities:  

Year:  2017        PMID： 29581598      PMCID： PMC5863883          DOI： 10.1177/0018578717746417

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN： 0018-5787


  8 in total

1.  Pharmacokinetics, Safety, and Tolerability of Glecaprevir and Pibrentasvir in Healthy White, Chinese, and Japanese Adult Subjects.

Authors:  Chih-Wei Lin; Sandeep Dutta; Bifeng Ding; Tianli Wang; Neddie Zadeikis; Armen Asatryan; Jens Kort; Andrew Campbell; Thomas Podsadecki; Wei Liu
Journal:  J Clin Pharmacol       Date:  2017-08-11       Impact factor: 3.126

2.  Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial.

Authors:  Xavier Forns; Samuel S Lee; Joaquin Valdes; Sabela Lens; Reem Ghalib; Humberto Aguilar; Franco Felizarta; Tarek Hassanein; Holger Hinrichsen; Diego Rincon; Rosa Morillas; Stefan Zeuzem; Yves Horsmans; David R Nelson; Yao Yu; Preethi Krishnan; Chih-Wei Lin; Jens J Kort; Federico J Mensa
Journal:  Lancet Infect Dis       Date:  2017-08-14       Impact factor: 25.071

3.  Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis.

Authors:  Paul Y Kwo; Fred Poordad; Armen Asatryan; Stanley Wang; David L Wyles; Tarek Hassanein; Franco Felizarta; Mark S Sulkowski; Edward Gane; Benedict Maliakkal; J Scott Overcash; Stuart C Gordon; Andrew J Muir; Humberto Aguilar; Kosh Agarwal; Gregory J Dore; Chih-Wei Lin; Ran Liu; Sandra S Lovell; Teresa I Ng; Jens Kort; Federico J Mensa
Journal:  J Hepatol       Date:  2017-04-13       Impact factor: 25.083

4.  High Efficacy of ABT-493 and ABT-530 Treatment in Patients With HCV Genotype 1 or 3 Infection and Compensated Cirrhosis.

Authors:  Edward Gane; Fred Poordad; Stanley Wang; Armen Asatryan; Paul Y Kwo; Jacob Lalezari; David L Wyles; Tarek Hassanein; Humberto Aguilar; Benedict Maliakkal; Ran Liu; Chih-Wei Lin; Teresa I Ng; Jens Kort; Federico J Mensa
Journal:  Gastroenterology       Date:  2016-07-25       Impact factor: 22.682

5.  Pharmacokinetic Interactions and Safety of Coadministration of Glecaprevir and Pibrentasvir in Healthy Volunteers.

Authors:  Chih-Wei Lin; Sandeep Dutta; Weihan Zhao; Armen Asatryan; Andrew Campbell; Wei Liu
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2018-02       Impact factor: 2.569

6.  Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment.

Authors:  Fred Poordad; Franco Felizarta; Armen Asatryan; Mark S Sulkowski; Robert W Reindollar; Charles S Landis; Stuart C Gordon; Steven L Flamm; Michael W Fried; David E Bernstein; Chih-Wei Lin; Ran Liu; Sandra S Lovell; Teresa I Ng; Jens Kort; Federico J Mensa
Journal:  Hepatology       Date:  2017-04-10       Impact factor: 17.425

7.  Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Coinfected With Hepatitis C Virus and Human Immunodeficiency Virus Type 1: The EXPEDITION-2 Study.

Authors:  Jürgen K Rockstroh; Karine Lacombe; Rolando M Viani; Chloe Orkin; David Wyles; Anne F Luetkemeyer; Ruth Soto-Malave; Robert Flisiak; Sanjay Bhagani; Kenneth E Sherman; Tatiana Shimonova; Peter Ruane; Joseph Sasadeusz; Jihad Slim; Zhenzhen Zhang; Suvajit Samanta; Teresa I Ng; Abhishek Gulati; Matthew P Kosloski; Nancy S Shulman; Roger Trinh; Mark Sulkowski
Journal:  Clin Infect Dis       Date:  2018-09-14       Impact factor: 9.079

8.  In Vitro Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS5A Inhibitor Pibrentasvir.

Authors:  Teresa I Ng; Preethi Krishnan; Tami Pilot-Matias; Warren Kati; Gretja Schnell; Jill Beyer; Thomas Reisch; Liangjun Lu; Tatyana Dekhtyar; Michelle Irvin; Rakesh Tripathi; Clarence Maring; John T Randolph; Rolf Wagner; Christine Collins
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.